FGF-19 is associated with the pharmacological treatment of active vitamin D3 and may improve MetS by improving serum lipid metabolism-related parameters such as HDL and TG in patients taking active vitamin D3 drugs. This evidence concerns the gene FGF19 and metabolic syndrome.